Aeglea BioTherapeutics Shares Patient Update for Phase 1/2 Clinical Trial

Aeglea BioTherapeutics (NASDAQ:AGLE) dosed two adults in the repeat dose part of its Phase 1/2 clinical trial of AEB1102 for the treatment of patients with Arginase 1 Deficiency.
As quoted in the press release:

Initial results from two adult patients enrolled in Part 1 of the trial, who were administered single ascending doses, demonstrated that pegzilarginase was well tolerated and reduced arginine levels in the blood.
“The initiation of the repeat dose part of the study is important given the encouraging initial results seen with single doses of pegzilarginase, as it will provide important insights into the effects of longer term arginine reduction in patients with this serious and progressive disease,” said James Wooldridge, M.D., chief medical officer of Aeglea. “Additionally, we are continuing our discussions with the FDA about including pediatric patients in the trial, and have initiated activities in Europe and Canada to reach more patients with this very rare disease.”

Click here to read the full press release.

Source: globenewswire.com